Overview

A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)

Status:
Completed
Trial end date:
2020-03-09
Target enrollment:
Participant gender:
Summary
Randomized, double-blind, placebo-controlled, parallel-group study comparing multiple doses of HTD1801 to placebo.
Phase:
Phase 2
Details
Lead Sponsor:
HighTide Biopharma Pty Ltd